Literature DB >> 19267199

Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's Disease.

José María Paredes1, Tomás Ripollés, Xavier Cortés, María Jesús Martínez, María Barrachina, Fernando Gómez, Eduardo Moreno-Osset.   

Abstract

Prospective study carried out on 24 consecutive patients with Crohn's Disease, using sonography to assess changes caused by biological therapy and its relationship with the clinical-biological response. The Crohn's Disease Activity Index, the plasma concentration of C-reactive protein and abdominal sonograms (to assess the thickness and Doppler flow grade of the bowel wall and to detect the presence of any complications) were carried out one week prior to the induction treatment and two weeks after. The biological therapy induced remission or a partial response in 46% and 25% of the patients, respectively. It also caused a significant reduction in the thickness of the bowel wall (P = 0.005) and Doppler flow (P = 0.02), leading to the disappearance of complications in 50% of the patients. Sonographic changes were significantly more marked in patients who achieved some type of clinical-biological response, in such a way that sonograms were improved in 65% (P = 0.001) and complications disappeared in 100% of patients (P = 0.005) compared to those patients who did not respond to treatment. However, sonographic normality was only achieved in five out of 17 (29%) reactive patients (P = 0.27). This fact may support the use of sonography as a technique for optimizing the biological treatment of Crohn's Disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19267199     DOI: 10.1007/s10620-009-0759-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?

Authors:  E Domènech; J Hinojosa; P Nos; E Garcia-Planella; E Cabré; I Bernal; M A Gassull
Journal:  Aliment Pharmacol Ther       Date:  2005-12       Impact factor: 8.171

2.  American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

Authors:  Michael Clark; Jean-Frederic Colombel; Brian C Feagan; Richard N Fedorak; Stephen B Hanauer; Michael A Kamm; Lloyd Mayer; Carol Regueiro; Paul Rutgeerts; William J Sandborn; Bruce E Sands; Stefan Schreiber; Stephan Targan; Simon Travis; Severine Vermeire
Journal:  Gastroenterology       Date:  2007-07       Impact factor: 22.682

3.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

4.  Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response.

Authors:  Ad A van Bodegraven; Cornelius E J Sloots; Richelle J F Felt-Bersma; Stephan G M Meuwissen
Journal:  Dis Colon Rectum       Date:  2002-01       Impact factor: 4.585

5.  Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening.

Authors:  G Maconi; F Parente; S Bollani; B Cesana; G Bianchi Porro
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

6.  Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease.

Authors:  Nils Homann; Ute Klarmann; Klaus Fellermann; Andreas Brüning; Rolf Klingenberg-Noftz; Thomas Witthöft; Eduard F Stange; Diether Ludwig
Journal:  Inflamm Bowel Dis       Date:  2005-02       Impact factor: 5.325

Review 7.  Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Authors:  P Rutgeerts; G Van Assche; S Vermeire
Journal:  Aliment Pharmacol Ther       Date:  2006-02-15       Impact factor: 8.171

8.  Role of US in detection of Crohn disease: meta-analysis.

Authors:  Mirella Fraquelli; Agostino Colli; Giovanni Casazza; Silvia Paggi; Alice Colucci; Sara Massironi; Piergiorgio Duca; Dario Conte
Journal:  Radiology       Date:  2005-07       Impact factor: 11.105

9.  Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent.

Authors:  Carla Serra; Guido Menozzi; Antonio Maria Morselli Labate; Francesco Giangregorio; Paolo Gionchetti; Marina Beltrami; Daniela Robotti; Fabio Fornari; Teresa Cammarota
Journal:  Eur J Radiol       Date:  2007-01-18       Impact factor: 3.528

Review 10.  Modern imaging of Crohn's disease using bowel ultrasound.

Authors:  Fabrizio Parente; Salvatore Greco; Mirko Molteni; Andrea Anderloni; Giovanni Maconi; Gabriele Bianchi Porro
Journal:  Inflamm Bowel Dis       Date:  2004-07       Impact factor: 5.325

View more
  17 in total

Review 1.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

Review 2.  Curriculum based clinical review: small bowel imaging in Crohn's disease.

Authors:  Tom L Kaye; Chris Wilkinson
Journal:  Frontline Gastroenterol       Date:  2015-03-05

Review 3.  Diagnostics in inflammatory bowel disease: ultrasound.

Authors:  Deike Strobel; Ruediger S Goertz; Thomas Bernatik
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

4.  Noninvasive evaluation of mucosal healing in inflammatory bowel diseases.

Authors:  Jun Kato; Sakiko Hiraoka; Asuka Nakarai; Masao Ichinose
Journal:  Clin J Gastroenterol       Date:  2012-11-28

5.  Clinical Impact of Sonographic Transmural Healing After Anti-TNF Antibody Treatment in Patients with Crohn's Disease.

Authors:  José María Paredes; Nadia Moreno; Patricia Latorre; Tomás Ripollés; María Jesús Martinez; José Vizuete; Eduardo Moreno-Osset
Journal:  Dig Dis Sci       Date:  2019-03-14       Impact factor: 3.199

6.  Intravenous Contrast-Enhanced Ultrasound for Assessing and Grading Postoperative Recurrence of Crohn's Disease.

Authors:  María Jesús Martínez; Tomás Ripollés; Jose María Paredes; Eduardo Moreno-Osset; Juan Manuel Pazos; Esther Blanc
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

Review 7.  Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?

Authors:  Marjorie Argollo; Paulo Gustavo Kotze; Pradeep Kakkadasam; Geert D'Haens
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09-02       Impact factor: 46.802

8.  Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy.

Authors:  Jonathan R Dillman; Soudabeh Fazeli Dehkordy; Ethan A Smith; Michael A DiPietro; Ramon Sanchez; Vera DeMatos-Maillard; Jeremy Adler; Bin Zhang; Andrew T Trout
Journal:  Pediatr Radiol       Date:  2017-04-18

9.  Contrast-enhanced ultrasound (CEUS) in Crohn's disease: technique, image interpretation and clinical applications.

Authors:  Tomás Ripollés; María J Martínez-Pérez; Esther Blanc; Fructuoso Delgado; José Vizuete; José M Paredes; José Vilar
Journal:  Insights Imaging       Date:  2011-08-10

10.  Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn's disease.

Authors:  Li Ma; Wenbo Li; Nan Zhuang; Hong Yang; Wei Liu; Weixun Zhou; Yuxin Jiang; Jianchu Li; Qingli Zhu; Jiaming Qian
Journal:  Therap Adv Gastroenterol       Date:  2021-06-09       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.